Wordt geladen...
Differences in MEK inhibitor efficacy in molecularly characterized low-grade serous ovarian cancer cell lines
Advanced or recurrent low-grade serous ovarian cancers (LGSC) are resistant to conventional systemic treatments. LGSC carry mutations in RAS or RAF, leading to several clinical trials evaluating MEK inhibitors (MEKi). As LGSC cell lines and xenografts have been difficult to establish, little is know...
Bewaard in:
| Gepubliceerd in: | Am J Cancer Res |
|---|---|
| Hoofdauteurs: | , , , , , , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
e-Century Publishing Corporation
2016
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5088288/ https://ncbi.nlm.nih.gov/pubmed/27822414 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|